keyword
MENU ▼
Read by QxMD icon Read
search

Leptomeningeal carcinomatosis

keyword
https://www.readbyqxmd.com/read/28178712/surgical-treatment-for-leptomeningeal-disease
#1
Andrey A Volkov, Andreas K Filis, Frank D Vrionis
BACKGROUND: Advancements in cancer treatment have led to more cases of leptomeningeal disease, which requires a multimodal approach. METHODS: Treatment modalities are reviewed from a neurosurgical standpoint, focusing on intrathecal chemotherapy and shunting devices. Potential complications and how to avoid them are discussed. RESULTS: The Ommaya reservoir and the chemoport are used for administering intrathecal chemotherapy. Use of ventriculo-lumbar perfusion can efficiently deliver chemotherapeutic agents and improve intracerebral pressure...
January 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28149755/state-of-the-art-of-chemotherapy-for-the-treatment-of-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#2
REVIEW
Alessandro Inno, Vincenzo Di Noia, Ettore D'Argento, Alessandra Modena, Stefania Gori
Chemotherapy is the mainstay of treatment of advanced non-small cell lung cancer (NSCLC) without molecular drivers. Despite a low penetration of central nervous system (CNS), chemotherapy drugs demonstrated encouraging activity against CNS metastases from NSCLC. Based on the available data, chemotherapy should be considered as an important part of the multidisciplinary treatment of CNS metastases. Particularly, platinum-based regimens represent the most active combinations and pemetrexed is associated with a meaningful clinical benefit for patients with non-squamous histology...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28138027/met-copy-number-gain-is-associated-with-gefitinib-resistance-in-leptomeningeal-carcinomatosis-of-egfr-mutant-lung-cancer
#3
Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano
Leptomeningeal carcinomatosis (LMC) occurs frequently in EGFR-mutant lung cancer, and develops acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This study aimed to clarify the mechanism of EGFR-TKI resistance in LMC and seek for a novel therapeutic strategy. We examined EGFR mutations, including the T790M gatekeeper mutation, in 32 re-biopsy specimens from 12 LMC and 20 extracranial lesions of EGFR-mutant lung cancer patients who became refractory to EGFR-TKI treatment. All the 32 specimens had the same baseline EGFR mutations, but the T790M mutation was less frequent in LMC specimens than in extracranial specimens (8% vs...
January 30, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28110254/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-patients-a-continuing-challenge-in-the-personalized-treatment-era
#4
REVIEW
J Remon, E Le Rhun, B Besse
Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer patients and up to 5% and 9% in ALK-rearranged and EGFR-mutant lung cancer patients, respectively. The prognosis remains poor despite systemic treatment, intrathecal chemotherapy, radiation therapy and personalized treatments in molecularly selected patients. However, new therapies with improved cerebral-spinal fluid penetration have been developed for subgroups of molecular selected patients indicating they could be promising therapeutic options for managing leptomeningeal disease...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28101027/bilateral-facial-nerve-paralysis-as-first-presentation-of-lung-cancer
#5
Shadi Hamouri, Duha Al Shorafat
Leptomeningeal carcinomatosis is rare, and its precise incidence is unknown. It is associated with a wide spectrum of solid and hematological malignancies. To complicate its diagnosis, the clinical presentation of leptomeningeal carcinomatosis can be variable. We report a case of a 38-year-old male with bilateral facial nerve paralysis as first presentation of lung adenocarcinoma. To our knowledge, this is the only case describing bilateral facial nerve palsy as the first and only manifestation of lung adenocarcinoma...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/28064206/retrospective-analysis-of-survival-in-patients-with-leptomeningeal-carcinomatosis-from-lung-adenocarcinoma-treated-with-erlotinib-and-gefitinib
#6
Jumpei Kashima, Yusuke Okuma, Maki Miwa, Yukio Hosomi
BACKGROUND: Leptomeningeal carcinomatosis is a relatively rare metastatic form of non-small cell lung cancer, which can impact prognosis. There is an increasing need for selecting suitable epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among those currently included in standard care for EGFR mutation-positive patients. We compared the efficacy of gefitinib and erlotinib in survival of patients with leptomeningeal carcinomatosis. PATIENTS AND METHODS: The medical records of 269 patients who received tyrosine kinase inhibitors at a single center were retrospectively reviewed...
January 6, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28030859/clinical-efficacy-of-afatinib-treatment-for-a-patient-with-leptomeningeal-carcinomatosis
#7
Yo Kawaguchi, Jun Hanaoka, Hideki Hayashi, Naoki Mizusaki, Hirotoshi Iihara, Yoshinori Itoh, Tadashi Sugiyama
Leptomeningeal metastases occur in 1% of patients with non-small-cell lung cancer. There have been several reports on the treatment of leptomeningeal metastases with afatinib. Our patient was a 41-year-old woman who had never smoked and was diagnosed with stage IV adenocarcinoma of the lung with an epidermal growth factor receptor (EGFR) mutation. She was treated with afatinib for the recurrence of leptomeningeal metastases. After the treatment with afatinib was initiated, the neurological symptoms dramatically regressed, and she achieved progression-free survival for 7 months...
December 29, 2016: Chemotherapy
https://www.readbyqxmd.com/read/27914156/-intratechal-chemotherapy-treatment-through-an-ommaya-reservoir-catheter-for-meningeal-carcinomatosis-a-single-centre-experience
#8
José Pedro Lavrador, Nuno Simas, Edson Oliveira, Manuel Herculano Carvalho
INTRODUCTION: Meningeal carcinomatosis is defined as tumour cells infiltration of leptomeninges and subarachnoid space. It is normally related with poor survival (2 - 5 months). The best multidisciplinary treatment for this condition is a matter of discussion. Patient's condition and the natural history of the disease should be considered in the decision making process. MATERIAL AND METHODS: Retrospective cohort analysis of patients submitted to Ommaya Reservoir placement due to systemic solid tumour meningeal carcinomatosis between 2006 and 2014...
August 2016: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/27854097/optimizing-the-delivery-of-antineoplastic-therapies-to-the-central-nervous-system
#9
REVIEW
Jarushka Naidoo, Hardik Panday, Sadhana Jackson, Stuart A Grossman
Despite significant advances in the treatment of systemic cancers, progress in the treatment of primary brain tumors has been quite modest. In addition, an increasing proportion of patients with systemic cancers are presenting with brain-only metastases. These observations highlight the critical role that the blood-brain barrier plays in preventing antineoplastic therapies from reaching the central nervous system in therapeutic concentrations. This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27847569/retrospective-analysis-of-cerebrospinal-fluid-profiles-in-228-patients-with-leptomeningeal-carcinomatosis-differences-according-to-the-sampling-site-symptoms-and-systemic-factors
#10
Youngbo Shim, Ho-Shin Gwak, Sohee Kim, Jungnam Joo, Sang-Hoon Shin, Heon Yoo
OBJECTIVE: Elevated cell counts and protein levels in cerebrospinal fluid (CSF) result from disease activity in patients with leptomeningeal carcinomatosis (LMC). Previous studies evaluated the use of CSF profiles to monitor a treatment response or predict prognosis. CSF profiles vary, however, according to the sampling site and the patient's systemic condition. We compared lumbar and ventricular CSF profiles collected before intraventricular chemotherapy for LMC and evaluated the association of these profiles with patients' systemic factors and LMC disease activity...
November 2016: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/27817234/-effective-systemic-palliative-chemotherapy-for-intracranial-metastases-of-breast-cancer
#11
István Sipőcz, Tamás Pintér, Zoltán Skaliczky, Tamás Kullmann
The authors present the history of two patients. The first patient, a 69-year-old woman was diagnosed with locally invasive triple negative breast cancer with pulmonary and cerebral metastases. Complete radiological remission of the clinically asymptomatic cerebral metastases was detected under systemic chemotherapy with carboplatin-docetaxel (75 mg/m(2)). Later, the patient received whole brain radiotherapy and a second line of chemotherapy. The overall survival was 20 months from the diagnosis of cerebral metastases with conservation of partial autonomy...
November 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27809457/effects-of-postoperative-radiotherapy-on-leptomeningeal-carcinomatosis-or-dural-metastasis-after-resection-of-brain-metastases-in-breast-cancer-patients
#12
Boram Ha, Seung Yeun Chung, Yeon-Joo Kim, Ho-Shin Gwak, Jong Hee Chang, Sang Hyun Lee, In Hae Park, Keun Seok Lee, Seeyoun Lee, Tae Hyun Kim, Dae Yong Kim, Seok-Gu Kang, Chang-Ok Suh
Purpose: In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods: Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015...
October 31, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27790117/rapid-response-to-high-dose-pulsatile-erlotinib-in-afatinib-refractory-leptomeningeal-carcinomatosis-from-adenocarcinoma-of-the-lung-a-case-report
#13
Frank S Fan
Leptomeningeal carcinomatosis occurred in an old female patient who was on a standard dose of afatinib for the treatment of her non-small cell lung cancer harboring an epidermal growth factor receptor gene mutation sensitive to tyrosine kinase inhibitors when extracranial lesions were still under control. Shifting to high-dose, pulsatile erlotinib dramatically saved her from the devastating condition in a very short period of time. Inadequate afatinib concentration in cerebrospinal fluid is reasonably suspected, and there is a call for clinical trials testing high-dose afatinib in leptomeningeal carcinomatosis...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27721269/prolonged-overall-survival-of-patients-with-leptomeningeal-carcinomatosis-from-nonsmall-cell-lung-cancer
#14
Yanfang Ju, Shengjie Sun, Jinliang Wang, Shunchang Jiao
Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27688614/intrathecal-trastuzumab-for-leptomeningeal-carcinomatosis-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#15
Seema Gulia, Sudeep Gupta, Ashish Singh
There has been recent increase in incidence of leptomeningeal carcinomatosis, possibly due to widespread use of adjuvant trastuzumab and its known poor CNS penetration. Currently there are limited therapeutic options for these patients and outcome is poor. We report two cases of women with HER2 positive breast cancer who developed leptomeningeal carcinomatosis for which they were treated with intrathecal trastuzumab in combination with systemic therapy. Both patients had rapid symptomatic benefit and radiological response and remained progression free for at least seven months...
July 2016: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/27672788/poster-21-leptomeningeal-carcinomatosis-presenting-as-tetraparesis-a-very-rare-case-of-small-cell-prostate-carcinoma
#16
Sean Bemanian, Viswanath Aluru, Pouyan Gohari, Marc Ross
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/27617103/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-initial-response-to-erlotinib-followed-by-relapse-despite-continuing-radiological-resolution-of-disease
#17
Alvin J X Lee, Rachel Benamore, Monika Hofer, Meenali Chitnis
A 60-year-old male was diagnosed with T3, N3, M1b epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma. Five months later he developed significant headaches, weakness and numbness of the left leg, and unsteadiness of gait. Magnetic resonance imaging (MRI) brain demonstrated subtle gyral enhancement indicative of early leptomeningeal infiltration. He was commenced on second-line erlotinib which improved his lower limb symptoms. Three months later he developed increased urinary frequency and redeveloped leg symptoms...
September 2016: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/27580550/promising-effects-of-afatinib-on-leptomeningeal-carcinomatosis-derived-from-erlotinib-resistant-lung-adenocarcinoma
#18
Akimasa Sekine, Terufumi Kato, Tae Iwasawa, Tomohisa Baba, Akihiro Suido, Haruyasu Sakuranaka, Masaaki Futaki, Takashi Ogura
We herein report a case of a 67-year-old woman previously treated with erlotinib for adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation in exon 19, which rapidly developed to progressive symptomatic leptomeningeal carcinomatosis. The primary tumor and lung metastases also worsened and the performance status (PS) score declined to 3. With a re-biopsy from the pulmonary metastases, the T790M mutation was detected by the cobas EGFR mutation test, but not the cycleave test, although an exon 19 deletion was detected by both of the tests...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27554216/-a-case-of-isolated-leptomeningeal-carcinomatosis-from-advanced-gastric-cancer
#19
Jung Geun Ji, Joo Won Chung, Seung Woo Nam, Seung Kyu Choi, Dong Won Lee, Dae In Kim, Byung Gwan Jeon, Yun Jae Shin
Leptomeningeal carcinomatosis (LMC) is rare metastatic form of gastric cancer. Most cases are diagnosed in the final stage after multiple distant metastasis. An 84-year-old woman was admitted with melena, headache and vomiting. Esophagogastroduodenoscopy showed an ulceroinfiltrating lesion at the stomach (Borrmann class III), and biopsy revealed a signet ring cell carcinoma. The abdominal-pelvic CT showed no evidence of metastasis. A sudden decrease of consciousness was noted, but the brain CT showed no active lesion while the brain MRI revealed enhancement of leptomeninges...
August 25, 2016: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/27553811/optimal-management-of-leptomeningeal-carcinomatosis-in-breast-cancer-patients-a-systematic-review
#20
REVIEW
Shaan Dudani, Sasha Mazzarello, John Hilton, Brian Hutton, Lisa Vandermeer, Ricardo Fernandes, Mohammed F K Ibrahim, Stephanie Smith, Habeeb Majeed, Khalid Al-Baimani, Jean-Michel Caudrelier, Risa Shorr, Mark Clemons
The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered...
December 2016: Clinical Breast Cancer
keyword
keyword
71957
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"